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August 21, 2012:722–9 LPA Genetic Variants and Risks for Vascular DiseasesObjectives The purpose of this study is investigate the effects of variants in the apolipoprotein(a) gene (LPA) on vascular
diseases with different atherosclerotic and thrombotic components.
Background It is unclear whether the LPA variants rs10455872 and rs3798220, which correlate with lipoprotein(a) levels
and coronary artery disease (CAD), confer susceptibility predominantly via atherosclerosis or thrombosis.
Methods The 2 LPA variants were combined and examined as LPA scores for the association with ischemic stroke (and
TOAST [Trial of Org 10172 in Acute Stroke Treatment] subtypes) (effective sample size [ne]  9,396); peripheral
arterial disease (ne  5,215); abdominal aortic aneurysm (ne  4,572); venous thromboembolism (ne  4,607);
intracranial aneurysm (ne  1,328); CAD (ne  12,716), carotid intima-media thickness (n  3,714), and angio-
graphic CAD severity (n  5,588).
Results LPA score was associated with ischemic stroke subtype large artery atherosclerosis (odds ratio [OR]: 1.27;
p  6.7  10–4), peripheral artery disease (OR: 1.47; p  2.9  10–14), and abdominal aortic aneurysm
(OR: 1.23; p  6.0  10–5), but not with the ischemic stroke subtypes cardioembolism (OR: 1.03; p  0.69) or
small vessel disease (OR: 1.06; p  0.52). Although the LPA variants were not associated with carotid intima-
media thickness, they were associated with the number of obstructed coronary vessels (p  4.8  10–12). Further-
more, CAD cases carrying LPA risk variants had increased susceptibility to atherosclerotic manifestations outside
of the coronary tree (OR: 1.26; p  0.0010) and had earlier onset of CAD (–1.58 years/allele; p  8.2  10–8)
than CAD cases not carrying the risk variants. There was no association of LPA score with venous thromboembolism
(OR: 0.97; p  0.63) or intracranial aneurysm (OR: 0.85; p  0.15).
Conclusions LPA sequence variants were associated with atherosclerotic burden, but not with primarily thrombotic
phenotypes. (J Am Coll Cardiol 2012;60:722–9) © 2012 by the American College of Cardiology FoundationMedicine, Division of Hematology, University of Ottawa/Ottawa Hospital Research
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LPA Genetic Variants and Risks for Vascular Diseases August 21, 2012:722–9Recent studies strongly support a causal relationship be-
tween circulating lipoprotein (a) (Lp[a]) and coronary artery
disease (CAD) (1–3). However, the pathophysiologic
mechanism of this relationship is unclear. Substantial ex-
perimental evidence supports the notion that Lp(a) has both
atherogenic and thrombogenic properties (4–7), suggesting
that Lp(a) may have a role in both atherosclerotic and
thrombotic aspects of arterial disease and potentially also in
venous thrombosis.
Alleles of 2 single nucleotide polymorphisms (SNPs) in
the LPA gene, rs10455872 and rs3798220, have been shown
to be associated with high plasma levels of Lp(a) and CAD
(1,8). The variants, which are poorly correlated (r2  0.001),
together explain about 36% of the variance in Lp(a) levels
(1). Each minor allele of rs10455872 (G; 6.2% frequency)
and rs3798220 (C; 1.4% frequency) increased log Lp(a) by
.08 and 1.15 standard deviation units and the risk for CAD
y 47% and 68%, respectively (1). Evidence for the associ-
tion between plasma Lp(a) and other atherosclerotic and
hrombotic diseases is weaker; some studies have supported
uch an association, but others have not (2,3,9–18). Fur-
hermore, it has not been established whether Lp(a), or
p(a) correlated variants, confer the same risks to all of the
schemic stroke TOAST (Trial of Org 10172 in Acute
troke Treatment) subtypes (19,20). Therefore, additional
nformation about the role of Lp(a) at different vascular sites
btained from relatively large datasets that supports or
efutes previously found associations is needed.
The objective of this study was to investigate the effects of
he LPA variants on the risks for vascular diseases with
ifferent atherosclerotic and thrombotic components, to
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e also tested for association with intracranial aneurysm
IA), an arterial disease without arteriosclerotic or throm-
otic etiology. Additionally, the effects of LPA SNPs on
therosclerotic burden, as well as on carotid intima-media
hickness (IMT), an early marker of atherosclerosis, were
xamined.
ethods
tudy populations. Samples from 35 case-control series
hat included patients with ischemic stroke (effective sample
ize [ne]  9,396), PAD (ne  5,215), AAA (ne  4,572),
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further description in the Online Appendix.
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August 21, 2012:722–9 LPA Genetic Variants and Risks for Vascular DiseasesGenotyping. DNA extraction and single SNP genotyping was
carried out with various high-throughput methods with
laboratory-specific quality-control procedures as detailed in
Online Table 1. As the LPA SNPs were not represented
on available genome-wide chips, genotypes for the Ice-
landic samples were imputed using methods previously
described (21).
Statistical analysis. For the main analyses, we assessed the
association between the outcome variables and the total number of
minor alleles of either SNP (rs3798220[C] or rs10455872[G]),
assuming that both minor alleles have the same effect on the
outcome. The effect of each SNP on the binary outcomes, as
reported in Online Table 2, was also assessed by comparing it
with the effect of the major alleles of both SNPs.
Logistic and linear regression models were used for binary
and quantitative outcomes, respectively, to test for linear trend
with allele score (LPA score defined as the number of minor
alleles of rs3798220 and rs10455872) to derive effect estimates,
standard errors, and 2-sided p values, assuming additive allelic
effects (on the linear or log scale as appropriate). These tests
were performed as implemented in NEMO (22), the
R-software, and STATA software version 10.
The IMT trait was logarithmically transformed before
analysis, and adjusted for age, sex, body mass index, physical
exercise, and study center (country of origin). Age at angiog-
raphy and sex were included as covariates in the linear regres-
sion model when fitting the number of affected coronary
vessels to the LPA score. In the combined analysis, additional
adjustments were made for study site and ethnicity.
To allow for the relatedness between subjects in the
GAIT (Genetic Analysis of Idiopathic Thrombophilia)
studies, the method of generalized estimating equations was
used as implemented in the generalized estimating equa-
tions package (23) for the R-software. For the Icelandic
studies, p values and 95% confidence interval (CI) of ORs
are given after adjustment for the relatedness of the subjects
and other possible population stratification using the
method of genomic control. As the association tests for
IMT in the Oxfordshire Family Blood Pressure studies were
not significant, no adjustments for relatedness were made.
A fixed-effects meta-analysis approach was used to esti-
mate an inverse-variance weighted average of the ORs from
all studies of each outcome category. Tests of whether
summary ORs were equal to 1, and whether the true effects
in all studies were the same (likelihood ratio chi-square
heterogeneity test) were performed. Allelic frequencies of
rs3798220(C) and rs10455872(G), provided in the introduc-
tion, are the average frequency of the 15 populations of
European origin examined in this study.
Given the number of traits tested, we considered p values
0.0017 significant, assuming a Bonferroni correction fac-
tor of 30. The power of the study to detect significant
association (p  0.0017, assuming an OR of 1.3) between
LPA score and ischemic stroke, PAD, AAA, or VTE, was
97%. The power was slightly less for the ischemic stroke
subtypes large artery atherosclerosis (LAA), cardioembo- nlism (CE), or small vessel dis-
ease (SVD), or 74%, 78%, and
52%, respectively, and for IA the
power was 34%. The power to
detect an association between
LPA score and IMT with effect
size 0.1 mm was 99%, at a p
value even as low as 0.0005. Pro-
spective studies have suggested
that a 0.1-mm increase in IMT is
associated with a 20% to 30%
increase in risk for developing
CAD (24,25), and each LPA mi-
nor allele increases the risk for
CAD by 20% to 30%. An effect
size of 0.1 mm per variant allele
could therefore be expected if the
effect of LPA variants on CAD
(or other atherosclerotic diseases)
was mediated entirely through
early atherogenesis and reflected
in changes in the carotid artery
IMT.
As the case-control ratios dif-
fered between studies, the effec-
tive sample size (ne), represent-
ng the sample size for cases in
hich the case-control ratio was 1, for each study was
alculated as the harmonic mean of the number of cases and
ontrols and is reported in Figures 1 and 2. For the Icelandic
studies, the effect sample size was further adjusted for
relatedness by dividing it by the genomic control inflation
factor. The combined effective sample sizes were used in the
power calculations.
Results
LPA SNP association with different vascular traits. The
associations between each SNP and the vascular diseases are
shown for all study groups in Online Tables 2A to 2D. As
the estimated effects of the 2 SNPs were not significantly
different, and the mechanisms by which both SNPs affect
Lp(a) have been suggested to be similar (1), for reasons of
simplicity (and to increase power) the main analyses
(Figs. 1 and 2, Tables 1, 2, and 3) report the effect estimates
for the 2 SNPs combined (LPA score), which assumes that
their effects are equal. LPA score results for each study group
are detailed in Online Tables 3A to 3C.
Results from all studies combined show nominally sig-
nificant association between the LPA score and ischemic
stroke overall, with an estimated OR of 1.10 (95% CI: 1.02
to 1.18; p  0.016) (Fig. 1). Ischemic stroke subtype
analysis revealed that the association is restricted to LAA
(OR: 1.27; 95% CI: 1.11 to 1.46; p  6.7  10–4), as the
ffects of LPA variants on the CE and SVD subtypes were
Abbreviations
and Acronyms
AAA  abdominal aortic
aneurysm
CAD  coronary artery
disease
CE  cardioembolism
CI  confidence interval
IA  intracranial aneurysm
IMT  intima-media
thickness
LAA  large artery
atherosclerosis
Lp(a)  apolipoprotein (a)
LPA  apolipoprotein(a) gene
MI  myocardial infarction
ne  effective sample size
OR  odds ratio
PAD  peripheral arterial
disease
SNP  single nucleotide
polymorphism
SVD  small vessel disease
TOAST  Trial of Org 10172
in Acute Stroke Treatment
VTE  venous
thromboembolismonsignificant (p  0.50). The LPA score was associated
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LPA Genetic Variants and Risks for Vascular Diseases August 21, 2012:722–9with both PAD (OR: 1.47; 95% CI: 1.33 to 1.62; p  2.9 
10–14) and AAA (OR: 1.23; 95% CI: 1.11 to 1.36; p  6.0 
0–5). The previously reported association between CAD
nd LPA score (1) in individuals of European ancestry was
onfirmed (OR: 1.32; 95% CI: 1.24 to 1.42; p  1.1 
0–15). In addition, the LPA score was associated with CAD
n African Americans (OR: 2.49; 95% CI: 1.08 to 5.72; p
.032) (Online Table 4). In contrast, the LPA score was not
ssociated with VTE (p  0.63), IA (p  0.15) (Fig. 1), or
ean common carotid IMT (p  0.083) (Table 1).
Figure 1 Association of LPA Score With Vascular Diseases
Forest plot of the associations of apolipoprotein(a) gene (LPA) score with ischemic
artery atherosclerosis [LAA], cardioembolism [CE], and small vessel disease [SVD
embolism (VTE), coronary artery disease (CAD), and intracranial aneurysm (IA) in in
indicated by squares, with an area in proportion to the sample size, and with horiz
tive sample sizes (ne) and p values for the associations.
Figure 2 Association of LPA Score With CAD, With and Withou
Other Vascular Territories, and With Age-Group at Ons
(A) Forest plot of the association of LPA score with CAD in Iceland, for cases with
after excluding cases with known CVD. ne Values, ORs, 95% CIs and p values are
of the association of LPA score with early onset CAD (diagnosed before the age o
age of 50 to 70 years in men and 60 to 75 years in women), and late onset C
pean origin from Iceland and Atlanta, Georgia, were combined using an inverse varianhe association of LPA score with PAD, LAA, and AAA
mong patients with and without concomitant CAD.
iven the substantial overlap between CAD and the other
therosclerotic diseases, it is conceivable that the associa-
ions of the LPA variants with LAA stroke, PAD, and AAA
re mediated through (or inflated by) the association of
hese diseases with CAD. Therefore, we reanalyzed the
ssociations between the LPA variants and the atheroscle-
otic phenotypes in cases with and without a history of
AD in studies in which this information was available
e, and TOAST (Trial of Org 10172 in Acute Stroke Treatment) subtypes (large
pheral arterial disease (PAD), abdominal aortic aneurysm (AAA), venous thrombo-
als of European origin. Combined odds ratios (ORs) from multiple studies are
lines representing the 95% confidence intervals (CIs). The plot shows the effec-
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CAD
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ars in men and 60 years in women), intermediate onset CAD (diagnosed at the
agnosed after age 70 years in men and 75 years in women). Individuals of Euro-
ghted meta-analysis approach (fixed-effects model). Abbreviations as in Figure 1.strok
]), peri
dividu
ontalt Ath
et of
conco
shown
f 50 ye
AD (di
ce–wei
A
E
c
1
a
t
A
c
C
(
a
1
a
t
r
0
a
o
l
D
W
(
A
v
t
n
a
C
t
t
t
s
W
727JACC Vol. 60, No. 8, 2012 Helgadottir et al.
August 21, 2012:722–9 LPA Genetic Variants and Risks for Vascular Diseases(Online Tables 5A and 5B). After the exclusion of data
from patients with CAD, the effect estimates for LPA score
became lower for PAD (OR: 1.17; p  0.12) and AAA
(OR: 1.11; p  0.16), suggesting a stronger association of
the LPA score with atherosclerotic disease manifested in
more than 1 vascular bed, although the effect estimate was
not lowered for LAA (OR: 1.30; p  0.013) (Online
Table 5A).
Association with CAD, with and without atherosclerosis
in other vascular territories. To investigate whether LPA
score increased the risk for a widespread atherosclerotic
disease, we divided the Icelandic CAD cases into those with
confirmed atherosclerosis related disease in other vascular
beds (PAD, AAA, or LAA), and those without a known
history of these diseases. While, for CAD with concomitant
PAD, AAA, and/or LAA the OR was 1.54 (p 
8.9  10–9), the OR for CAD without known PAD, AAA,
and/or LAA was 1.22 (p  2.4  10–7). On direct
comparison of the 2 groups of CAD cases, each LPA risk
allele increased the risk for atherosclerosis in other vascular
beds by 26% (p  0.0010) (Fig. 2).
Association with angiographic extent of CAD and with
MI among patients with angiographic CAD. Online
Table 6 shows the distribution of the number of affected
(50% stenosis) coronary index vessels, and the proportions
with MI among 5,588 subjects who had undergone coro-
nary angiography. After adjusting for sex, age at angiogra-
Association of LPA Score With Carotid IMT*Table 1 Association of LPA Score With Carotid IMT*
Study Group N
IMTlog (mm)
p Value phet Value SE
IMPROVE 2,984 –0.0064 0.0036 0.076 —
Oxfordshire Family
Blood Pressure
Study
730 –0.0002 0.0224 0.99 —
Combined 3,714 –0.0060 0.0036 0.083 0.70
*Linear regression coefficients () with corresponding standard errors (SE) and p values, assuming
additive allelic effects. The model included age, sex, body mass index, and physical exercise as
covariates. Additional adjustments were made for study site (country) for the IMPROVE study.
IMPROVE  Carotid Intima Media Thickness and IMT-PRogression as Predictors of Vascular
Events in a High Risk European Population; IMT intima-media thickness; LPA apolipoprotein(a)
gene; phet  p value for heterogeneity test.
Association of LPA Scoreith Angiographic CAD Severity*Table 2 Asso iation of LPA ScoreWith Angiographic CAD Severity*
Study Group N
No. of Affected
Coronary Index
Vessels
p Value SE
Iceland 2,330 0.245 0.061 5.8  10–5
Atlanta-European American 2,718 0.281 0.052 6.3  10–8
Atlanta-African American 540 0.396 0.219 0.071
Combined 5,588 0.267 0.038 4.8  10–12
*Linear regression coefficients () with corresponding standard errors (SE) and p values, assuming
additive allelic effects. Age at angiography and sex were included as covariates in the model for
each study group. In the combined analysis additional adjustments were made for study groupv
(site/ethnicity).
CAD  coronary artery disease; LPA  apolipoprotein(a) gene.phy, study site, and ethnicity, in a linear regression model,
each LPA risk allele increased the number of diseased vessels
by a mean of 0.267 (p  4.8  10–12). Effect estimates for
frican Americans were similar to those of patients of
uropean origin (Table 2). In a logistic regression model
omparing patients with angiographic CAD with MI (n 
,817) or without MI (n  1,908), the LPA score was not
ssociated with MI after adjusting for the same variables and
he age at first CAD diagnosis (OR: 0.99; p  0.90).
ssociation with age of onset of CAD and MI. The
orrelation between LPA score and the age at diagnosis of
AD was tested, with adjustments for sex and study site
Table 3, Fig. 2). Each LPA risk allele was associated with
mean of 1.58 years’ earlier diagnosis of CAD (p  8.2 
0–8) among 9,276 cases of European origin from Iceland
nd Atlanta, Georgia (Online Table 4). Restricting data to
hose from cases with MI diagnoses, the corresponding
eduction in age at diagnosis of first MI was 0.92 years (p
.028). Effect estimates for age at first CAD diagnosis
mong 333 African Americans were consistent with those
bserved for whites, but did not reach nominal significance
evels.
iscussion
e report an association between 2 Lp(a)-related SNPs
combined and measured as LPA score), and the PAD,
AA, and LAA subtype of ischemic stroke, with each
ariant allele increasing the risk by 47%, 23%, and 27% for
he 3 diseases, respectively. In contrast, our analyses show
o association between the LPA variants and VTE or CE
nd SVD stroke subtypes. We show that patients with
AD carrying LPA risk alleles have increased susceptibility
o atherosclerotic manifestations outside of the coronary
ree and are more likely to be diagnosed earlier with CAD
han are CAD cases not carrying these variants. Further, our
tudy provides evidence for an association between the LPA
Association Between LPA Scoreand the Age at Diag osis of CAD*Table 3 Associati n Betwe n LPA Scoreand the Age at Diagnosis of CAD*
Parameter n
Age at Diagnosis
p Value SE
European ancestry
Age at first CAD diagnosis 9,275 –1.581 0.295 8.2 10–8
Age at first MI 5,148 –0.918 0.416 0.028
Age at first CAD diagnosis
for MI cases
5,148 –1.334 0.400 0.00085
African Americans
Age at first CAD diagnosis 333 –3.541 2.521 0.16
Age at first MI 185 –2.221 3.249 0.50
Age at first CAD diagnosis
for MI cases
185 –6.009 3.159 0.059
*Linear regression coefficients () with corresponding standard errors (SE) and p values, assuming
additive allelic effects. The model included sex as a covariate. In addition, study site (Iceland/
Atlanta) was a covariate in the model when analyzing those of European ancestry.
MI  myocardial infarction. Other abbreviations as in Table 2.ariants and the number of coronary arteries (out of 4 index
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implication, Lp(a) levels, have an effect on the atheroscle-
rotic burden of large vessels throughout the arterial tree. To
the best of our knowledge, relationships between sequence
variants affecting Lp(a) levels and either systemic distribu-
tion of atherosclerosis or angiographic CAD severity, have
not been reported before. However, several studies, that in
general have been limited by small sample sizes, have
assessed the association between Lp(a) levels and severity of
CAD and provided conflicting results (26–30).
In apparent contrast to the correlation between LPA score
and earlier age at onset of CAD, LPA score was not
associated with IMT, a marker for subclinical atherosclero-
sis (31,32). This is consistent with results from a recent
population-based cohort study showing that Lp(a) levels
(and SNPs correlated with Lp[a]), were not associated with
IMT (33), and in line with a recent meta-analysis of
genome-wide association studies from the CHARGE (Co-
horts for Heart and Aging Research in Genomic Epidemi-
ology) consortium (34) that found little evidence for genetic
overlap across carotid IMT and CAD. We suggest that the
effects of the LPA variants, and thus Lp(a) levels, on the risk
for atherosclerotic manifestations are mediated at later
stages in the pathogenic pathway and are thus not reflected
by variation in carotid IMT.
Our study was limited by the fact that measurements of
Lp(a) levels were not available, rendering it impossible to
show directly that the association of the LPA risk variants
with atherosclerotic phenotypes is mediated through Lp(a)
levels. Therefore, the possibility that the risk conferred by
the LPA score is mediated through mechanisms other than
increased Lp(a) levels, cannot be disregarded. However,
previous studies have shown a strong and consistent asso-
ciation between the 2 LPA variants and Lp(a) levels (1,35),
and the association between the LPA risk variants and CAD
has been shown to disappear with Lp(a) level adjustments
(1), strongly supporting the view that the effect on athero-
sclerotic phenotypes is mediated through Lp(a) levels.
Lp(a) has been implicated in both atherogenesis and
thrombosis. We show that LPA risk alleles that correlate
with high plasma Lp(a) levels were associated with vascular
diseases with a strong atherosclerotic component, such as
CAD, PAD and LAA, and AAA, but we failed to dem-
onstrate an association between LPA alleles and diseases
without an atherosclerotic etiology, such as VTE and IA, or
diseases less related to atherosclerosis, such as the CE and
SVD stroke subtypes. Furthermore, among patients with
angiographic CAD, after adjustments for age at onset of
CAD, the LPA variants were not associated with MI,
indicating that the risk is mediated through atherosclerotic
plaque deposition, rather than plaque rupture, or subsequent
thrombosis. Given the assumption that the risk for LPA
variants on vascular diseases is mediated through Lp(a)
levels, our results suggest that the implicit thrombogenic
properties of Lp(a) (4,5) are insufficient to increase the risksfor the thrombotic stroke subtypes CE and SVD, or to
promote VTE.
Conclusions
We report an association between 2 variants in the LPA
gene and 3 atherosclerosis-related diseases (i.e., the LAA
subtype of ischemic stroke, PAD, and AAA). In addition to
replicating the previously reported association between the
LPA variants and CAD, we report a correlation between the
LPA variants and the number of obstructed coronary arter-
ies. Furthermore, the risk variants were associated with an
earlier diagnosis of CAD. Evaluating LPA risk alleles may
therefore contribute to more effective primary and secondary
prevention of atherosclerotic disease. In contrast, we found
no association with the CE and SVD ischemic stroke
subtypes, which have less obvious atherosclerotic compo-
nents, or VTE, a primarily thrombotic disease. These
findings imply that the risk conferred by high Lp(a) levels is
mediated through the atherosclerotic, rather than the
thrombotic, aspects of vascular disease.
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